Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
Mallinckrodt
AstraZeneca
US Department of Justice
Accenture
Cerilliant
Julphar
Teva

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,981,571

« Back to Dashboard

Title: Benzodioxa alkylene ethers as melatonergic agents
Abstract:Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.
Inventor(s): Catt; John D. (Southington, CT), Johnson; Graham (Madison, CT), Keavy; Daniel J. (Killingworth, CT), Mattson; Ronald J. (Meriden, CT), Parker; Michael F. (Middletown, CT), Takaki; Katherine S. (Middletown, CT), Yevich; Joseph P. (Southington, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Oct 09, 1998
Application Number:09/169,784
Claims:1. A compound of Formula I or a pharmaceutically acceptable solvate thereof having the Formula: ##STR28## wherein Q.sup.1 and Q.sup.2 each are independently hydrogen or halogen;

X is oxygen;

Y is (CH.sub.2).sub.n, with n=1-4;

Z is oxygen;

R is hydrogen, halogen or C.sub.1-4 alkyl in both cases;

m is 1 or2;

R.sup.1 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-3 haloalkyl, C.sub.1-6 alkylamino, C.sub.2-6 alkenyl, C.sub.1-4 alkoxy(C.sub.1-4)alkyl, C.sub.1-4 alkylthio(C.sub.1-4)alkyl or C.sub.1-4 trifluoromethylalkyl; and

R.sup.2 is hydrogen or C.sub.1-4 alkyl.

2. The compound of claim 1 wherein Q.sup.1 and Q.sup.2 are independently hydrogen or iodo and m is 1.

3. The compound of claim 2 wherein R.sup.1 is C.sub.1-6 alkyl, C.sub.3-4 cycloalkyl, C.sub.1-3 haloalkyl, C.sub.2-3 alkenyl, C.sub.1-2 alkoxy(C.sub.1-2)alkyl or C.sub.1-2 trifluoromethylalkyl and R.sup.2 is hydrogen.

4. The compound of claim 3 wherein X is oxygen, Y is (CH.sub.2)n in which n is 1or 2 and Z is oxygen.

5. The compound of claim 4, selected from the group consisting of:

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]acetamide;

(-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]acetamide;

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]propanamide;

(-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl] propanamide;

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]butanamide;

(-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl] butanamide;

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]cyclopropane carboxamide;

(-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl] cyclopropane carboxamide;

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]-2-methylpropanam ide;

(-)-(trans)-N-[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]-2-methylpropa namide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]p ropanamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]a cetamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]c yclopropanecarboxamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]b utanamide;

(+)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]p ropenamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]t rifluoroacetamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl) cycloprop-1-yl]methyl]-3,3,3-trifluoropropanamide;

(+)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]p ropanamide;

(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]-methyl]acet amide;

(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]-methyl]prop anamide;

(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]-methyl]buta namide;

(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]-2-me thylpropanamide; and

(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]-methyl]cycl opropane carboxamide.

6. The compound of claim 5, selected from the group consisting of:

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]acetamide;

(-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]acetamide;

(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl]propanamide;

and (-)-(trans)-N-[[2-(1,3-benzodioxol-4-yl)cycloprop-1-yl]methyl] propanamide.

7. The compound of claim 5, selected from the group consisting of:

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]p ropanamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]a cetamide;

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]c yclopropanecarboxamide; and

(-)-(trans)-N-[[2-(2,3-dihydro-1,4-benzodioxin-5-yl)cycloprop-1-yl]methyl]b utanamide.

8. A method of treating sleep disorders in a patient in need of such treatment comprising administering to said patient a therapeutic amount of a compound of claim 1.

9. A composition useful for treating sleep disorders comprising a therapeutic amount of a compound of claim 1 and a suitable amount of a pharmaceutically acceptable carrier.

10. A method of treating circadian rhythm-related disorders in a patient in need of such treatment comprising administering to said patient a therapeutic amount of a compound of claim 1.

11. A composition useful for treating circadian rhythm-related disorders comprising a therapeutic amount of a compound of claim 1 and a suitable amount of a pharmaceutically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
US Department of Justice
Moodys
QuintilesIMS
Accenture
Fuji
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.